Screener
Stoke Therapeutics, Inc. STOK Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | 39,673 | 32,676 |
| Sales, general and administrative | 19,974 | 14,653 |
| Total operating expenses | 59,647 | 47,329 |
| (Loss) income from operations | (53,418) | 111,240 |
| Other income (expense): | ||
| Interest income (expense), net | 3,397 | 2,889 |
| Other income | 18 | 28 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s other operating expenses?
- Stoke Therapeutics, Inc. (STOK) reported other operating expenses of $59.65M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s other operating expenses changed year-over-year?
- Stoke Therapeutics, Inc.'s other operating expenses increased by 26.0% year-over-year, from $47.33M to $59.65M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s other operating expenses?
- Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s other operating expenses has grown at a 24.2% compound annual growth rate (CAGR), from $86.07M to $205.01M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Stoke Therapeutics, Inc.'s other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude